BACKGROUND: The UBE4B gene, which is located on chromosome 1p36, encodes a ubiquitin ligase that interacts with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), a protein involved in epidermal growth factor receptor (EGFR) trafficking, suggesting a link between EGFR trafficking and neuroblastoma pathogenesis. The authors analyzed the roles of UBE4B in the outcomes of patients with neuroblastoma and in neuroblastoma tumor cell proliferation, EGFR trafficking, and response to EGFR inhibition. METHODS: The association between UBE4B expression and the survival of patients with neuroblastoma was examined using available microarray data sets. UBE4B and EGFR protein levels were measured in patient tumor samples, EGFR degradation rates were measured in neuroblastoma cell lines, and the effects of UBE4B on neuroblastoma tumor cell growth were analyzed. The effects of the EGFR inhibitor cetuximab were examined in neuroblastoma cells that expressed wild-type and mutant UBE4B. RESULTS: Low UBE4B gene expression is associated with poor outcomes in patients with neuroblastoma. UBE4B overexpression reduced neuroblastoma tumor cell proliferation, and UBE4B expression was inversely related to EGFR expression in tumor samples. EGFR degradation rates correlated with cellular UBE4B levels. Enhanced expression of catalytically active UBE4B resulted in reduced sensitivity to EGFR inhibition. CONCLUSIONS: The current study demonstrates associations between UBE4B expression and the outcomes of patients with neuroblastoma and between UBE4B and EGFR expression in neuroblastoma tumor samples. Moreover, levels of UBE4B influence neuroblastoma tumor cell proliferation, EGFR degradation, and response to EGFR inhibition. These results suggest UBE4B-mediated growth factor receptor trafficking may contribute to the poor prognosis of patients who have neuroblastoma tumors with 1p36 deletions and that UBE4B expression may be a marker that can predict responses of neuroblastoma tumors to treatment.
BACKGROUND: The UBE4B gene, which is located on chromosome 1p36, encodes a ubiquitin ligase that interacts with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), a protein involved in epidermal growth factor receptor (EGFR) trafficking, suggesting a link between EGFR trafficking and neuroblastoma pathogenesis. The authors analyzed the roles of UBE4B in the outcomes of patients with neuroblastoma and in neuroblastoma tumor cell proliferation, EGFR trafficking, and response to EGFR inhibition. METHODS: The association between UBE4B expression and the survival of patients with neuroblastoma was examined using available microarray data sets. UBE4B and EGFR protein levels were measured in patienttumor samples, EGFR degradation rates were measured in neuroblastoma cell lines, and the effects of UBE4B on neuroblastoma tumor cell growth were analyzed. The effects of the EGFR inhibitor cetuximab were examined in neuroblastoma cells that expressed wild-type and mutant UBE4B. RESULTS: Low UBE4B gene expression is associated with poor outcomes in patients with neuroblastoma. UBE4B overexpression reduced neuroblastoma tumor cell proliferation, and UBE4B expression was inversely related to EGFR expression in tumor samples. EGFR degradation rates correlated with cellular UBE4B levels. Enhanced expression of catalytically active UBE4B resulted in reduced sensitivity to EGFR inhibition. CONCLUSIONS: The current study demonstrates associations between UBE4B expression and the outcomes of patients with neuroblastoma and between UBE4B and EGFR expression in neuroblastoma tumor samples. Moreover, levels of UBE4B influence neuroblastoma tumor cell proliferation, EGFR degradation, and response to EGFR inhibition. These results suggest UBE4B-mediated growth factor receptor trafficking may contribute to the poor prognosis of patients who have neuroblastoma tumors with 1p36 deletions and that UBE4B expression may be a marker that can predict responses of neuroblastoma tumors to treatment.
Authors: Kai-Oliver Henrich; Matthias Fischer; Daniel Mertens; Axel Benner; Ruprecht Wiedemeyer; Benedikt Brors; André Oberthuer; Frank Berthold; Jun Stephen Wei; Javed Khan; Manfred Schwab; Frank Westermann Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Shahab Asgharzadeh; Roger Pique-Regi; Richard Sposto; Hong Wang; Yujun Yang; Hiroyuki Shimada; Katherine Matthay; Jonathan Buckley; Antonio Ortega; Robert C Seeger Journal: J Natl Cancer Inst Date: 2006-09-06 Impact factor: 13.506
Authors: Ruth Ho; Jane E Minturn; Tomoro Hishiki; Huaqing Zhao; Qun Wang; Avital Cnaan; John Maris; Audrey E Evans; Garrett M Brodeur Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: Yang Lu; Xinqun Li; Ke Liang; Rodney Luwor; Zahid H Siddik; Gordon B Mills; John Mendelsohn; Zhen Fan Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701
Authors: Susanne Schlisio; Rajappa S Kenchappa; Liesbeth C W Vredeveld; Rani E George; Rodney Stewart; Heidi Greulich; Kristina Shahriari; Nguyen V Nguyen; Pascal Pigny; Patricia L Dahia; Scott L Pomeroy; John M Maris; A Thomas Look; Matthew Meyerson; Daniel S Peeper; Bruce D Carter; William G Kaelin Journal: Genes Dev Date: 2008-03-11 Impact factor: 11.361
Authors: Helena Carén; Katarina Ejeskär; Susanne Fransson; Luke Hesson; Farida Latif; Rose-Marie Sjöberg; Cecilia Krona; Tommy Martinsson Journal: Mol Cancer Date: 2005-03-01 Impact factor: 27.401
Authors: Michael D Prados; Sara A Byron; Nhan L Tran; Joanna J Phillips; Annette M Molinaro; Keith L Ligon; Patrick Y Wen; John G Kuhn; Ingo K Mellinghoff; John F de Groot; Howard Colman; Timothy F Cloughesy; Susan M Chang; Timothy C Ryken; Waibhav D Tembe; Jeffrey A Kiefer; Michael E Berens; David W Craig; John D Carpten; Jeffrey M Trent Journal: Neuro Oncol Date: 2015-05-01 Impact factor: 12.300
Authors: Leena Ackermann; Michael Schell; Wojciech Pokrzywa; Éva Kevei; Anton Gartner; Björn Schumacher; Thorsten Hoppe Journal: Nat Struct Mol Biol Date: 2016-09-26 Impact factor: 15.369
Authors: Sarah B Whittle; Sahily Reyes; Melissa Du; Monica Gireud; Linna Zhang; Sarah E Woodfield; Michael Ittmann; Michael E Scheurer; Andrew J Bean; Peter E Zage Journal: J Pediatr Hematol Oncol Date: 2016-03 Impact factor: 1.289
Authors: Monica Gireud-Goss; Sahily Reyes; Ritika Tewari; Anthony Patrizz; Matthew D Howe; Julia Kofler; M Neal Waxham; Louise D McCullough; Andrew J Bean Journal: Mol Cell Neurosci Date: 2020-08-22 Impact factor: 4.314
Authors: Sarah E Woodfield; Rong Jun Guo; Yin Liu; Angela M Major; Emporia Faith Hollingsworth; Sandra Indiviglio; Sarah B Whittle; Qianxing Mo; Andrew J Bean; Michael Ittmann; Dolores Lopez-Terrada; Peter E Zage Journal: Genes Cancer Date: 2016-01